US equities
|
INTC
$63.85
▼-30.65%
AMZN
$237.74
▼-2.48%
NVDA
$201.75
▼-5.57%
MU
$867.08
▼-7.19%
SNDK
$1,129.58
▼-15.07%
GOOGL
$278.30
▼-1.94%
AMD
$496.17
▼-12.40%
SPCX
$136.03
▼-5.46%
INTC
$63.85
▼-30.65%
AMZN
$237.74
▼-2.48%
NVDA
$201.75
▼-5.57%
MU
$867.08
▼-7.19%
SNDK
$1,129.58
▼-15.07%
GOOGL
$278.30
▼-1.94%
AMD
$496.17
▼-12.40%
SPCX
$136.03
▼-5.46%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Bicara Therapeutics Inc. - Common Stock
(NQ:
BCAX
)
8.865
-0.865 (-8.89%)
Delayed Quote
Updated: 2:26 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicara Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
↗
March 26, 2026
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 19, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 05, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 12, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
December 15, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
December 06, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
December 01, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
November 20, 2025
Via
Investor Brand Network
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
November 20, 2025
From
BioMedWire
Via
GlobeNewswire
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
Via
Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
These stocks that are showing activity before the opening bell on Monday.
↗
October 13, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
October 13, 2025
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
4 Biotech Stocks Seeing Explosive Momentum Gains
↗
October 07, 2025
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...
Via
Benzinga
Topics
ETFs
Stocks
Bicara Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
June 11, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 04, 2025
Via
Benzinga
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
June 01, 2025
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
↗
May 23, 2025
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.
Via
Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
May 23, 2025
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
< Previous
1
2
3
Next >
